REG - Verici Dx PLC - Notice of Results and Business Update

Verici DxAnnouncement

11/07/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240711:nRSK0926Wa&default-theme=true

RNS Number : 0926W  Verici Dx PLC  11 July 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Notice of Results and Business Update

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it will report its interim results for the
six months to 30 June 2024, together with a business update, on 15 July 2024.

 

Investor roadshow and briefings

 

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial
Officer, will provide a live online presentation via the Investor Meet Company
platform on Tuesday 16th July 2024 at 16:30 BST. This presentation is open to
all existing and potential shareholders. Questions can be submitted pre-event
via the Investor Meet Company dashboard up until 9.00 am BST the day before
the meeting or during the live presentation. Investors can sign up to Investor
Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor
(https://www.investormeetcompany.com/verici-dx-plc/register-investor)

 

The Company will also be presenting in person at The Novotel, London on
Wednesday 17 July 2024 at 18.00 BST as part of the regular series of "Shares"
investor events hosted by AJ Bell. Existing shareholders and potential
investors can register to attend this live evening event for free at: Shares
Magazine - Events
(https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-london-live-event-170724)

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Phil Davies / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORRBMBTMTABBII